| Old Articles: <Older 6291-6300 Newer> |
|---|
 |
IndustryWeek
April 21, 2010 |
Letters To the Editor For May 2010 Making sense of health care.   |
The Motley Fool
April 21, 2010
Brian Orelli |
Yawn! Get Back to Me Next Quarter, J&J There's more stagnant growth from the health-care giant. |
The Motley Fool
April 20, 2010
Jim Mueller |
Better, Targeted Drugs, Dead Ahead Personalized medicine is becoming a reality that will help patients, companies, and investors. |
The Motley Fool
April 20, 2010
Brian Orelli |
Drug Sales Down! Should We Celebrate? Amylin won't have completed results for a trial comparing Bydureon to Victoza until next year. But until that data is in, it might not be as easy to get the patients back as Amylin is making it out to be. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
BusinessWeek
April 15, 2010
Naomi Kresge |
As the Pill Turns 50, a Rivalry Heats Up With underserved markets in Asia beckoning, Teva is taking on Bayer, the leader in oral contraceptives |
BusinessWeek
April 15, 2010
Kanoko Matsuyama |
Looking East, Big Pharma Cuts Prices Drugmakers are beginning to choose sales volume over high margins to tap the massive Asian market |
The Motley Fool
April 13, 2010
Brian Orelli |
Teva Gets Less Generic The generic-drug maker makes a major push into branded-drug development. |
The Motley Fool
April 12, 2010
Brian Orelli |
Pay for Our Drugs or Else Is the pharmaceutical industry's muscle strong enough? In the U.S., health-care reform will increase coverage, but the reform's ability to keep prices in check is fairly limited. |
The Motley Fool
April 9, 2010
Brian Orelli |
Is Boston Scientific Turning It Around? Selling off a pair of units could help. |
| <Older 6291-6300 Newer> Return to current articles. |
